Verastem, Inc. (VSTM) Form 424B5 — Oct 14, 2026
Verastem filed a preliminary prospectus supplement (424B5) for an underwritten offering of common stock and pre-funded warrants, with joint book-runners Jefferies, Guggenheim Securities, and Cantor. Final share counts and pricing are left blank pending completion, with the stock last trading at $7.45 on October 13, 2026. Net proceeds are intended to fund continued clinical development of VS-7375, a selective oral KRAS G12D dual ON/OFF inhibitor, plus working capital and general corporate purposes. The company suspended and terminated its existing ATM prospectus in connection with the deal.
Key figures
- Offering Price
- 0
- Shares Outstanding
- 90481615
- Rsus outstanding
- 3701673
- Lockup period days
- 60
- Net tangible book value
- $34.1 million ($0.38 per share as of June 30, 2026)
- Last reported sale price
- $7.45 (Oct 13, 2026)
- Stock options outstanding
- 3343705
- Prefunded warrant exercise price
- $0.0001 per share
- Existing prefunded warrant shares
- 9727142
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.